Targeting Angiogenesis as a Promising Modality for the Treatment of Prostate Cancer

被引：9

作者：

Lin, Jianqing ^{[1
]}

Kelly, William K. ^{[1
]}

机构：

[1] Thomas Jefferson Univ, Jefferson Kimmel Canc Ctr, Dept Med Oncol, Philadelphia, PA 19107 USA

来源：

UROLOGIC CLINICS OF NORTH AMERICA | 2012年 / 39卷 / 04期

关键词：

Antiangiogenic therapy; Prostate cancer; Angiogenesis; Treatment; ENDOTHELIAL GROWTH-FACTOR; PHASE-II TRIAL; TUMOR ANGIOGENESIS; C-MET; ANDROGEN RECEPTOR; VEGF EXPRESSION; COMBINATION; BEVACIZUMAB; DOCETAXEL; SUNITINIB;

D O I：

10.1016/j.ucl.2012.07.010

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Antiangiogenic therapy has been successful for the treatment of solid tumors. Several strategies have been used to target angiogenesis in prostate cancer. These strategies include blocking proangiogenic factors via monoclonal antibodies or small molecule inhibitors targeting downstream signaling effector pathways, or using agents with immune-modulatory effects. This review examines the general concepts of tumor angiogenesis and the key clinical trials that have used these agents and other novel biologics in prostate cancer. Targeting angiogenesis is still a promising treatment strategy in prostate cancer with a rational trial design and combination approach.

引用

页码：547 / +

页数：15

共 50 条

[21] Oncolytic Virus as a Novel Modality for the Treatment of Prostate Cancer
Lu, Meng
Wei, Fukun
Ma, Sai
Xu, Ziyang
Wang, Jie
Yang, Chunhua
Mao, Lijun
DISCOVERY MEDICINE, 2021, 32 (167) : 133 - 139
[22] Combined modality treatment for prostate cancer: Role of chemotherapy
Sandler, HM
Narayan, S
Smith, DC
SEMINARS IN ONCOLOGY, 2003, 30 (04) : 95 - 100
[23] Radiation therapy for prostate cancer: An evolving treatment modality
Chen, Ronald C.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (09) : 579 - 581
[24] RACIAL DISPARITIES IN RADIATION TREATMENT MODALITY FOR PROSTATE CANCER
Alameddine, Mitchell B.
Wu, Shan
Orikogbo, Oluwaseun
Sharbaugh, Danielle
Yabes, Jonathon
Obiora, Daisy
Stencel, Michael G.
Davies, Benjamin J.
Sabik, Lindsay
Jacobs, Bruce L.
JOURNAL OF UROLOGY, 2024, 211 (05): : E1132 - E1133
[25] Proteolysis Targeting Chimera (PROTAC) as a promising novel therapeutic modality for the treatment of triple-negative breast cancer (TNBC)
Dogheim, Gaidaa M.
Amralla, Mohamed T.
DRUG DEVELOPMENT RESEARCH, 2023, 84 (04) : 629 - 653
[26] Natural and synthetic agents targeting inflammation and angiogenesis for chemoprevention of prostate cancer
Araldi, Elena M. V.
Dell'Aica, Isabella
Sogno, Ilaria
Lorusso, Girieca
Garbisa, Spiridione
Albini, Adriana
CURRENT CANCER DRUG TARGETS, 2008, 8 (02) : 146 - 155
[27] Tumour angiogenesis and response in combined modality treatment of head and neck cancer
Dobrowsky, E
Lang, S
Dobrowsky, W
EUROPEAN JOURNAL OF CANCER, 1999, 35 : S105 - S105
[28] Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment
Grande, Enrique
Bolos, Maria-Victoria
Arriola, Edurne
MOLECULAR CANCER THERAPEUTICS, 2011, 10 (04) : 569 - 579
[29] Tumor treating fields: narrative review of a promising treatment modality for cancer
Kutuk, Tugce
Atak, Ece
La Rosa, Alonso
Kotecha, Rupesh
Mehta, Minesh P.
Chuong, Michael D.
CHINESE CLINICAL ONCOLOGY, 2023, 12 (06)
[30] Targeting copper metabolism: a promising strategy for cancer treatment
Kong, Ruimin
Sun, Guojuan
FRONTIERS IN PHARMACOLOGY, 2023, 14

← 1 2 3 4 5 →